Completed OBSERVATIONAL NCT02409134

Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat

Cognitive Function and Patient-Reported Psychological and Functional/Quality of Life Outcomes Investigation in Patients Taking Vorinostat for Graft-versus-Host Disease Prophylaxis

Sponsor: Sung Choi, M.D.

Conditions Graft-vs-Host Disease Quality of Life

Updated 8 times since 2017 Last updated: Jun 13, 2018 Started: Apr 30, 2015 Primary completion: Apr 30, 2018 Completion: Apr 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02409134, this observational or N/A phase trial focuses on Graft-vs-Host Disease and Quality of Life and remains completed. Sponsored by Sung Choi, M.D., it has been updated 8 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Feb 2019 — Jan 2021 [monthly]

Completed
Jul 2018 — Feb 2019 [monthly]

Completed

Status: Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Jul 2018 [monthly]

Recruiting
Apr 2018 — Jun 2018 [monthly]

Recruiting

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Recruiting NA

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sung Choi, M.D.

Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ann Arbor, United States